Mazdutide

Mazdutide is a synthetic peptide classified as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). It is a long-acting analog of oxyntomodulin, designed to engage both receptors to modulate metabolic pathways relevant to obesity and related disorders. Chemically, mazdutide is a linear peptide composed of 33 amino acids. Its structure includes a conjugation of a C20 fatty diacid moiety attached via a hydrophilic linker to a lysine residue. This fatty-acid conjugation is a strategic modification that extends the peptide’s half-life, enabling less frequent dosing schedules. This design principle is consistent with other long-acting GLP-1 receptor agonists used in research and clinical development.

Mazdutide is identified by development codes IBI362 and LY3305677, reflecting its origin from Innovent Biologics, with certain territorial licensing agreements granted to Eli Lilly. The molecular formula of mazdutide is C₂₀₇H₃₁₇N₄₅O₆₅, and it is registered under PubChem CID 167312357 and CAS number 2259884-03-0. Pharmacologically, in vitro binding assays demonstrate mazdutide’s affinity for human and mouse GLP-1 and glucagon receptors, with Ki values in the low nanomolar range: 17.7 nM for human GCGR, 15.9 nM for mouse GCGR, 28.6 nM for human GLP-1R, and 25.1 nM for mouse GLP-1R. Functionally, mazdutide stimulates insulin secretion from mouse pancreatic islets with an EC50 of 5.2 nM, indicating potent receptor activation relevant to glucose metabolism.

From a regulatory perspective, mazdutide holds a unique status. It has been approved by China’s National Medical Products Administration (NMPA) as of April 2026 for the treatment of obesity, marking it as a real pharmaceutical drug within that jurisdiction. However, mazdutide is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication. No public filings for new drug applications (NDA) or investigational new drug (IND) applications have been announced by Innovent Biologics or its U.S. partners. This regulatory distinction positions mazdutide as an approved medication in China but as an investigational or unapproved compound in the United States and Europe.

Research-grade mazdutide is available through specialized peptide suppliers for laboratory research use only. This research material is distinct from the pharmaceutical-grade product marketed in China and is not intended for human consumption or clinical use outside approved jurisdictions.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Research on mazdutide, a dual GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist peptide, has demonstrated significant efficacy in weight reduction and glycemic control in clinical settings within China. Mazdutide is a long-acting synthetic oxyntomodulin analog, structurally characterized as a 33-amino-acid linear peptide conjugated to a C20 fatty diacid moiety via a hydrophilic linker at a lysine residue, which extends its half-life to allow for less-frequent dosing. The compound exhibits potent receptor pharmacology, binding human GCGR with a Ki of 17.7 nM and human GLP-1R with a Ki of 28.6 nM, while stimulating insulin secretion from mouse pancreatic islets with an EC50 of 5.2 nM. Its molecular formula is C207H317N45O65, and it is identified by PubChem CID 167312357 and CAS 2259884-03-0.

Importantly, mazdutide has been approved by China’s National Medical Products Administration (NMPA) for the treatment of obesity as of April 2026. However, it remains unapproved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for any indication, with no publicly announced Investigational New Drug (IND) or New Drug Application (NDA) filings in the United States. Thus, mazdutide occupies a unique regulatory position as an approved pharmaceutical in China but an investigational compound in other major markets. At Verified Peptides, we offer research-grade mazdutide material that is distinct from the pharmaceutical product approved in China and intended solely for laboratory research use, not for human consumption.

The clinical efficacy of mazdutide has been evaluated in multiple Phase 3 trials involving Chinese adults with obesity or obesity complicated by type 2 diabetes. The GLORY-1 Phase 3 trial enrolled 610 Chinese adults with obesity and administered a 6 mg dose of mazdutide. This trial demonstrated approximately 13% placebo-subtracted weight reduction at week 32, indicating robust weight loss efficacy with this dosing regimen.

The GLORY-2 Phase 3 trial, published in a peer-reviewed journal (PubMed PMID 42251595), evaluated a higher 9 mg dose of mazdutide in Chinese adults with obesity. This trial reported weight loss of up to 20.1%, meeting the primary endpoint and all key secondary endpoints. The GLORY-2 results underscore the dose-dependent efficacy of mazdutide and its potential as a potent anti-obesity agent in the studied population.

Additional data from the DREAMS-3 trial, a head-to-head comparison of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity, were announced as topline results by the sponsoring company. In this trial, mazdutide demonstrated superiority over semaglutide on the primary composite endpoint, defined as achieving both HbA1c below 7.0% and at least 10% body-weight reduction from baseline at week 32. Specifically, 48.0% of mazdutide-treated participants met this composite endpoint compared to 21.0% in the semaglutide group, with a statistically significant p-value of less than 0.0001. This head-to-head data highlights mazdutide’s dual receptor agonism as a potentially more effective mechanism for combined glycemic and weight management in this population.

These trials were conducted with the pharmaceutical formulation of mazdutide approved in China, and their data are accessible through PubMed and NIH resources for further scientific review. The research-grade mazdutide compound sold for laboratory investigation allows researchers to explore its dual GLP-1R/GCGR agonist mechanism in vitro and in vivo models, supporting ongoing discovery and mechanistic studies independent of the pharmaceutical product’s clinical use.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Mazdutide is distinguished within the peptide agonist landscape by its dual receptor targeting, acting as a GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist. This dual mechanism differentiates it from the more common single-receptor GLP-1 agonists such as semaglutide and liraglutide, which are widely studied and utilized in research settings. By engaging both GLP-1R and GCGR, mazdutide mimics the endogenous hormone oxyntomodulin, potentially offering a broader metabolic impact through simultaneous modulation of insulin secretion and energy expenditure pathways. This mechanistic profile aligns it conceptually with other multi-receptor agonists like tirzepatide and retatrutide, which target additional receptors, though mazdutide’s specific dual action on GLP-1R and GCGR sets it apart in terms of receptor selectivity and pharmacodynamic effects.

A key lesser-known fact about mazdutide is its regulatory status, which is unique among peptides discussed on this site. It has received formal approval from China’s National Medical Products Administration (NMPA) for the treatment of obesity as of April 2026, marking an important milestone for dual-agonist peptides in clinical application. This approval reflects robust clinical evidence from Phase 3 trials in Chinese adults demonstrating significant weight loss efficacy at doses of 6 mg and 9 mg. However, mazdutide remains unapproved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and no U.S. regulatory filings have been publicly announced. This creates a distinct regulatory and research-use context: while mazdutide is a marketed pharmaceutical in China, it is available internationally only as a research-grade compound for laboratory investigation, not for human use.

Further highlighting mazdutide’s research significance is the DREAMS-3 trial, a head-to-head comparison against semaglutide in Chinese adults with type 2 diabetes and obesity. Mazdutide demonstrated a statistically significant superiority on a composite endpoint of glycemic control and weight reduction, achieving 48.0% responder rate versus 21.0% for semaglutide (p<0.0001). This finding provides a valuable comparative data point supporting the potential advantages of dual GLP-1R/GCGR agonism over single-receptor GLP-1 agonism in metabolic disease models. Researchers investigating receptor-specific mechanisms, metabolic regulation, or novel obesity and diabetes therapeutics may find mazdutide’s profile and emerging clinical data particularly informative for designing studies or interpreting dual-agonist pharmacology.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Research-grade mazdutide supplied for laboratory investigation is manufactured and sourced under stringent quality control measures to ensure consistency and reliability for experimental applications. At Verified Peptides, we provide mazdutide as a distinct, non-pharmaceutical product that is chemically identical to the active peptide sequence used in the approved drug formulation in China but is not intended for human consumption or clinical use. Our mazdutide material undergoes comprehensive analytical validation including third-party Certificates of Analysis (COA) which document batch-specific data on purity and identity.

Purity assessment is primarily conducted through high-performance liquid chromatography (HPLC), confirming that the mazdutide peptide exceeds 95% purity thresholds suitable for research use. This level of purity is critical to minimize confounding variables in experimental protocols and to maintain reproducibility across studies. Additionally, mass spectrometry is employed to verify the molecular identity of the peptide, including confirmation of the 33-amino-acid sequence and the presence of the C20 fatty diacid conjugated via the hydrophilic linker at the lysine residue. This dual analytical approach ensures that the compound used in vitro or in vivo research precisely matches the expected molecular structure.

It is important to emphasize that research-grade mazdutide is supplied exclusively for laboratory research purposes and is not the pharmaceutical product approved by China’s National Medical Products Administration (NMPA). The pharmaceutical-grade drug formulation is subject to additional regulatory manufacturing standards and clinical-grade quality controls, which differ from those applied to research materials. At Verified Peptides, we maintain rigorous sourcing protocols to guarantee that our mazdutide research compound supports high-quality, reproducible scientific investigation without implying clinical safety or efficacy.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Research-grade mazdutide, as a synthetic 33-amino-acid peptide conjugated to a C20 fatty diacid moiety, requires careful storage and handling to maintain its stability and bioactivity in laboratory settings. Typically supplied as a lyophilized powder, mazdutide should be stored at -20°C or colder to preserve peptide integrity over extended periods. Avoid exposure to moisture and repeated freeze-thaw cycles, which can degrade peptide structure and reduce experimental reproducibility. Upon reconstitution, it is recommended to use sterile, chilled aqueous solvents such as water for injection or buffered saline solutions, avoiding extreme pH or organic solvents that may destabilize the peptide.

Once reconstituted, mazdutide solutions should be aliquoted into single-use portions to minimize freeze-thaw events and stored at 2–8°C if used within a short timeframe, generally no longer than 24 to 48 hours. For longer-term storage, aliquots can be frozen at -80°C, but repeated thawing should be strictly avoided. The fatty acid conjugation extending the half-life in vivo does not confer additional stability benefits ex vivo; thus, standard peptide handling protocols apply. Researchers should monitor for any signs of precipitation or discoloration upon thawing or prior to use, which may indicate degradation.

Overall, adherence to these storage and handling guidelines ensures that mazdutide retains its dual GLP-1 receptor and glucagon receptor agonist properties for reliable in vitro or in vivo laboratory investigations.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.